Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jan-Dec:22:15347354231185110.
doi: 10.1177/15347354231185110.

Neurological Outcomes of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer: A Systematic Review and Meta-Analysis

Katsuyoshi Suzuki  1 , Shinichiro Morishita  2 , Jiro Nakano  3 , Taro Okayama  1 , Junichiro Inoue  4 , Takashi Tanaka  5 , Takuya Fukushima  3
Affiliations
Meta-Analysis

Neurological Outcomes of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer: A Systematic Review and Meta-Analysis

Katsuyoshi Suzuki et al. Integr Cancer Ther. 2023 Jan-Dec.

Abstract

Background: This systematic review and meta-analysis aimed to determine whether chemotherapy-induced peripheral neuropathy (CIPN) affects the risk of falls and physical function in patients with cancer.

Methods: A literature search was conducted in the CINAHL, Scopus, and PubMed databases for articles published from January 1950 to April 2022. Seven review authors retrieved studies using predetermined eligibility criteria, extracted the data, and evaluated the quality.

Results: Nine studies were included in the analysis. Patients with CIPN had a significantly higher risk of falls than those without CIPN (risk ratio = 1.38, 95% confidence interval [CI] =1.18-1.62). Patients with CIPN had lower grip strength (standardized mean difference [SMD] =-0.42, 95% CIs = -0.70 to -0.14, P = .003), longer chair stand time (SMD = 0.56, 95% CIs = -0.01 to 1.17, P = .05), worse timed up and go test time (SMD = 0.79, 95% CIs = 0.41 to 1.17, P < .0001), and lower mean Fullerton Advanced Balance scale score (SMD = -0.81, 95% CIs = -1.27 to -0.36, P = .005) than patients without CIPN. There were no significant differences in gait speed (P = .38) or Activities-specific Balance Confidence Scale score (P = .09) between patients with and without CIPN.

Conclusions: This systematic review and meta-analysis demonstrated that patients with CIPN are prone to falls and impaired balance function and muscle strength.

Keywords: cancer; chemotherapy; chemotherapy-induced peripheral neuropathy; fall; oncology; physical function.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flow chart of the article selection process.
Figure 2.
Figure 2.
Risk ratio for falls associated with chemotherapy-induced peripheral neuropathy in patients with cancer. Abbreviations: CIPN, chemotherapy-induced peripheral neuropathy; CI, confidence interval.
Figure 3.
Figure 3.
Influence of chemotherapy-induced peripheral neuropathy on physical function. (A) Gait speed. (B) Chair stand. (C) Grip strength. (D) Timed up and go test. (E) Activities specific balance confidence scale. (F) Fullerton advanced balance scale. Abbreviations: CIPN, chemotherapy-induced peripheral neuropathy; SD, standard deviation; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Yu A, Street D, Viney R, et al. Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. Support Care Cancer. 2021;29:6379-6387. doi: 10.1007/s00520-021-06196-8 - DOI - PubMed
    1. Salgado TM, Quinn CS, Krumbach EK, et al. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study. Support Care Cancer. 2020;28:4163-4172. doi: 10.1007/s00520-019-05254-6 - DOI - PMC - PubMed
    1. Boyette-Davis JA, Cata JP, Driver LC, et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol. 2013;71:619-626. doi: 10.1007/s00280-012-2047-z - DOI - PMC - PubMed
    1. Boyette-Davis JA, Walters ET, Dougherty PM. Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Manag. 2015;5:285-296. doi: 10.2217/pmt.15.19 - DOI - PMC - PubMed
    1. Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. Brain Behav. 2017;7:e00558. doi: 10.1002/brb3.558 - DOI - PMC - PubMed

MeSH terms

Substances